<DOC>
	<DOCNO>NCT02060435</DOCNO>
	<brief_summary>The investigator analyze clinical outcome DLBCL patient accord age group define impact EBV status clinical outcome .</brief_summary>
	<brief_title>Epstein-Barr Virus Status Diffuse Large B Cell Lymphoma</brief_title>
	<detailed_description>Epstein-Barr virus ( EBV ) positive diffuse large B-cell lymphoma ( DLBCL ) recognize new provisional entity 2008 World Health Organization ( WHO ) classification tumor hematopoietic lymphoid tissue . This lymphoma define EBV+ clonal B-cell proliferation immunocompetent adult older 50 year . To denote patient age definition disease , age cutoff define old 50 year . However , cutoff clearly arbitrary without scientific background . knowledge EBV+DLBCL young adult scanty . This EBV+DLBCL young adult disease entity distinct disease form EBV+DLBCL elderly .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Pathologically confirm de novo DLBCL , accord World Health Organization ( WHO ) classification : register Samsung Medical Center ( SMC ) Lymphoma Cohort Study I/II ( ClinicalTrials.gov Identifier : NCT00822731 , NCT01877109 ) identify Asan Medical Center ( AMC ) medical database : adequate amount quality paraffinembedded biopsy specimen unstained slide EBVencoded RNA ( EBER ) situ hybridization . Patients unknown EBV status , primary central nervous system ( CNS ) lymphoma , posttransplant lymphoproliferative disorder ( PTLDs ) , HIVpositive DLBCL exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>diffuse large B-cell lymphoma</keyword>
	<keyword>Ebstein-Barr Virus</keyword>
</DOC>